| Name | Ginsenoside Rg3 | ||
| PubChem CID | 9918693 | ||
| Molecular Weight | 785.0g/mol | ||
| Synonyms |
20(R)-ginsenoside Rg(3), 20(S)-ginsenoside Rg(3), 20s-ginsenoside rg3, 3-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyldammar-24-ene-3beta,12beta,20s-triol, beta-D-glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-, ginsenoside 20-rg3, ginsenoside Rg(3), ginsenoside Rg3, ginsenoside rg3, (+)-, ginsenoside rg3, (s)-, s-ginsenoside rg3 |
||
| Formula | C₄₂H₇₂O₁₃ | ||
| SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C | ||
| InChI | 1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1 | ||
| InChIKey | RWXIFXNRCLMQCD-JBVRGBGGSA-N | ||
| CAS Number | 14197-60-5 | ||
| ChEMBL ID | CHEMBL398412 | ||
| ChEBI ID | CHEBI:67991 | ||
| KEGG ID | C20778 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | RenShen | ||
| Use Part | Root | ||
| Habitat | JiLin, LiaoNing, HeiLongJiang | ||
| Flavor | Sweet; Slightly Bitter | ||
| Meridian Tropism | Spleen; Lung; Heart; Kidney | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Araliaceae
-->Genus: Panax
-->Species: Panax ginseng
|
||
| Pair Name | Ginsenoside Rg3, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Inhibition-->Glycolysis | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | HK2 | hsa3099 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| BEL-7404 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6568 | |
| Result | Rg3 has a synergistic effect on the sensitivity of HepG2 and Bel7404 hepatoma cells to SFN, which is related to HK2-mediated glycolysis and the PI3K/Akt signaling pathway. | |||
| Pair Name | Ginsenoside Rg3, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BAX | hsa581 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Phosphorylation | PDK1 | hsa5163 | |
| Up-regulation | Expression | PTEN | hsa5728 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
| In Vivo Model | Huh7 cells (1×10⁶) in 100 μL PBS were injected subcutaneously into the flank of nude mice. Mice (N = 5 of each group) were randomly divided into four groups once the tumor volume reached 0.2 cm*3. | |||
| Result | These findings suggest a promising strategy for HCC treatment, which could be performed in a sufficiently frequent manner. | |||
| Pair Name | Ginsenoside Rg3, Endostar | |||
| Partner Name | Endostar | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | BECN1 | hsa8678 | |
| Down-regulation | Expression | MAPK8 | hsa5599 | |
| Down-regulation | Expression | MMP2 | hsa4313 | |
| Down-regulation | Expression | MMP9 | hsa4318 | |
| Down-regulation | Expression | MTOR | hsa2475 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| Down-regulation | Expression | SQSTM1 | hsa8878 | |
| Down-regulation | Expression | VEGFA | hsa7422 | |
| Down-regulation | Expression | VEGFB | hsa7423 | |
| Down-regulation | Expression | VEGFC | hsa7424 | |
| In Vivo Model | MCF-7 cells were inoculated under right mammary gland of female C57 mice. | |||
| Result | Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit angiogenesis and cell invasion, and enhance cell autophagy. | |||
| Pair Name | Ginsenoside Rg3, Tamoxifen | |||
| Partner Name | Tamoxifen | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Inhibition-->Glycolysis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | PFKFB3 | hsa5209 | |
| Down-regulation | Expression | PFKM | hsa5213 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| T-47D | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0553 | |
| HEK293T | Healthy | Homo sapiens (Human) | CVCL_0063 | |
| In Vivo Model | A total of 6×10⁶ cells were suspended in 100 μL of a 1:1 mixture of Matrigel and phosphate-buffered saline (PBS),and then injected into the flanks of nude mice. | |||
| Result | This study highlights the contribution of Rg3 in enhancing the therapeutic efficacy of TAM in breast cancer, and suggests that targeting TAM-resistant PFKFB3 overexpression may represent a promising strategy to improve the response to combination therapy in breast cancer. | |||
| Pair Name | Ginsenoside Rg3, Doxorubicin | |||
| Partner Name | Doxorubicin | |||
| Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
| Biological Phenomena | Inhibition-->Angiogenesis | |||
| In Vitro Model | 143B | Osteosarcoma | Homo sapiens (Human) | CVCL_2270 |
| U2OS | Osteosarcoma | Homo sapiens (Human) | CVCL_0042 | |
| In Vivo Model | Ginsenoside Rg3 combined with doxorubicin inhibits tumour growth and lung metastasis in 143B-derived murine osteosarcoma models. | |||
| Result | We concluded that the combination of ginsenoside Rg3 and doxorubicin displayed an evidently synergistic effect, which has the potential to be used as an effective and safe therapeutic approach for OS treatment. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway. Bioengineered. 2022 May;13(5):13919-13928. doi: 10.1080/21655979.2022.2074616. | Click |
| 2 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. Biomed Pharmacother. 2018 Jan;97:1282-1288. doi: 10.1016/j.biopha.2017.11.006. | Click |
| 3 | Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice. Asian Pac J Trop Med. 2016 Feb;9(2):180-3. doi: 10.1016/j.apjtm.2016.01.010. | Click |
| 4 | Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biol Int. 2024 Jan 15. doi: 10.1002/cbin.12123. | Click |
| 5 | Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. J Pharm Pharmacol. 2023 Nov 23;75(11):1405-1417. doi: 10.1093/jpp/rgad070. | Click |
